Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 3 extension study of LP352 (bexicaserin) in developmental and epileptic encephalopathies
CTR20253931Phase 3Active
- Sponsor
- Longboard Pharmaceuticals
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bexicaserin in epileptic encephalopathy, Dravet syndrome, Lennox-Gastaut syndrome (LGS), sponsored by Longboard Pharmaceuticals. Started Feb 2026; status: active.
02
Drugs
bexicaserin
03
Conditions
epileptic encephalopathyDravet syndromeLennox-Gastaut syndrome (LGS)
Beyond the preview
Go deeper on CTR20253931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253931.